Neuros Medical, a California-based medical device company, named David Veino as president and CEO. In this planned transition, Veino will also join the board of directors, where he’ll succeed Thomas Wilder, who is joining the board as an independent director.
“On behalf of the entire Neuros board, I would like to thank Tom for his leadership and commitment to the company over the past six years as president and CEO,” said Casey Tansey, Neuros director. “Tom guided the company through its formative years and has built a strong strategy and foundation for the company’s future.”
Veino has served as the company’s COO since 2018, where he guided the company through completion of the clinical trial that evaluated Neuros’ Altius High Frequency Nerve Block System for patients with intractable post-amputation pain. Upon anticipated premarket approval (PMA) from the US Food and Drug Administration (FDA), Veino will lead Neuros’ transition of from an early-stage company to its commercial execution stage.
Veino has 25 years of senior management experience. Prior to Neuros, he held positions at Stryker, Globus Medical, and Cardiovascular Systems.
The company also appointed Randy Ban as an independent director to its board. Ban currently serves as chief commercial officer of Inspire Medical Systems.
“The Neuros team is thrilled to have Randy join our board,” Veino said. “His experience and insights will be invaluable after the anticipated PMA approval, as we prepare to transition to a commercial stage company with a continued focus on delivering strong and consistent patient outcomes.”
